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Measurements
Subjects used a self-reported questionnaire to document medical history, current medication, family history, clinical symptoms, smoking habits (current or nonsmoker), and alcohol intake (current or nondrinker). Systolic and diastolic BP were measured by using a mercury manometer, placed on the right arm of seated subjects who had rested in a sitting position for at least 5 min before the measurement. Measurement was carried out twice, with the mean value used for statistical analysis. Blood samples were collected in a fasting state from the antecubital vein with subjects in a sitting position, and samples were transferred immediately to chilled tubes.
Hypertension was defined as systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg, and/or the use of anti-hypertensive medication. Diabetes mellitus was ascertained either by self-reported physical diagnosis, fasting blood sugar (FBS) ≥126 mg/dl, hemoglobin (Hb) A1c value ≥6.5%, and/or the use of anti-diabetes mellitus medication. Hypercholesterolemia was ascertained by measurement of serum total cholesterol ≥220 mg/dl and/or the use of anti-hyperlipidemic medication. Body mass index (BMI) was calculated from as weight (kg) divided by the square of height (m 2 ). Obesity was defined as BMI ≥25.0 kg/m 2 both in men and women. 9 Serum creatinine (Cr) was measured by the enzymatic method, and creatinine clearance (CCr) was estimated using the Cockcroft-Gault equation, 10 including a correction factor of 0.85 for women. 11 A standard 12-lead ECG was recorded after subjects had rested sufficiently. All ECGs were read by cardiologists and classified according to the Minnesota Code (MC) revised edition in 1982. The criteria are used as a standard to classify ECG morphology for objective comparisons between various populations. 12 
Assay of H-FABP Levels
Blood samples for measurements of serum H-FABP concentrations were drawn and centrifuged at 2,500 G for 15 min at 4°C within 30 min of collection, and the obtained serum was stored at -70°C until analysis. H-FABP levels were measured using a 2-step sandwich enzyme-linked immunosorbent assay (ELISA) kit (MARKIT-M H-FABP, Dainippon Pharmaceutical Co Ltd, Tokyo, Japan) as reported previously. 5 The calibrators for the ELISA covered the range 0-250 ng/ml. Cut-off value of H-FABP (4.3 ng/ml) was used from our previous study data. 13 
Development of Reference Limits
Partitioning of reference limits is considered necessary, if measured values vary according to physiologic characteristics. Reference limits were determined for each gender and age using 5 th , 25 th , 95 th , and 97.5 th percentile values.
Statistical Analyses
We used Student's t-test to evaluate differences in means and chi-square test to evaluate differences in proportions. For comparison of mean values among quartiles, one-factor analysis of variance (ANOVA) was used. Linear regression analysis was used for correlation of H-FABP levels with several continuous or categorical variables including age, gender, BMI, systolic and diastolic BP, uric acid, and CCr, respectively. Variables selected in the univariate linear regression analysis (regression coefficient >0.1) were followed by the multivariate linear regression analysis. Furthermore, the multiple logistic regression analysis was used to assess the contribution of each independent variable to a high serum H-FABP level (≥4.3 ng/ml). Data are expressed as mean ± SD. All statistical analysis was carried out using the software of Stat View version 5 (SAS Institute Inc, Cary, NC, USA). All probability values were 2-tailed and all confidence intervals were estimated at the 95% level. Abbreviations see in Table 1 .
Results
Characteristics of Subjects
Baseline characteristics of 2,099 subjects that were entered into the final analysis are shown in Table 1 . Overall, mean age was 62±10 years. Among them there were 933 males (44%), 1,303 subjects (62%) with hypertension, 205 subjects (10%) with diabetes, 670 subjects (32%) with hypercholesterolemia, 705 subjects (34%) with obesity, and 542 subjects (26%) with high H-FABP levels. The mean serum H-FABP levels were 3.64±1.54 ng/ml. Age, systolic and diastolic BP, triglyceride, Cr, FBS, uric acid, H-FABP level, the percentages of hypertension, diabetes mellitus, smoking, drinking, and ECG abnormalities (I°AVB and LVH) were significantly higher in men than in women. On the other hand, total cholesterol, high-density lipoprotein, CCr, percentages of hyperlipidemia, and ST-T abnormality by ECG were significantly higher in women than in men.
Influence of Gender and Aging on H-FABP Levels
Serum H-FABP levels were higher in men than in women as shown in Table 1 . In addition, serum H-FABP levels showed an increase with aging (Fig 1) . Serum H-FABP levels were affected by both gender and aging.
Reference Limits
Because H-FABP was affected by gender and age, we carried out separate analyses for men and women, and developed reference limits for all ages and for each of 4 age groups. Upper reference limits (95 th and 97.5 th percentile) and lower reference limits (5 th and 25 th percentile) for H-FABP are listed in Table 2 . As indicated, percentiles varied greatly across different age and gender categories.
Correlation of H-FABP Levels With Physiologic Variables
The analyses of univariate and multivariate regression models using clinical variables are shown in Table 3 systolic BP, BMI, HbA1c, CCr, and ECG abnormality scores were identified as the determinants of H-FABP. After multivariable adjustment, age, BMI, CCr, and ECG abnormality scores were associated with H-FABP levels significantly (regression coefficient >0.100 and p<0.05). Thus, it was suggested that aging, BMI, and renal function might affect serum H-FABP levels. ECG abnormality score had a significant correlation with H-FABP levels. This may suggest the association between elevated serum H-FABP levels and latent myocardial damage. Next, we examined the odds ratios of each factor with a high serum H-FABP level (≥4.3 ng/ml) using the multiple logistic regression analysis (Table 4) . Age, BMI, and ECG abnormality score were positively associated and CCr was negatively associated with high serum H-FABP levels.
Graded Relation Between Serum H-FABP Levels and ECG Abnormality Score
Next, we investigated the association between serum H-FABP levels and ECG abnormality, which may reflect latent myocardial damage. Patients were divided into 4 groups based on H-FABP levels ( 4-ng/ml, n=521]). In the highest 4 th quartile, age, systolic and diastolic BP, BMI, Cr, FBS, HbA1c, uric acid level, ECG abnormality scores were higher, and CCr was lower than the other 3 quartiles. The highest 4 th quartile of H-FABP levels was associated with the highest rates of hypertension, obesity, and ECG abnormalities (LVH, ST-T abnormality and PVC). Elevated serum H-FABP levels were associated with aging, high levels of BP, Cr, and uric acid, all of which were risk factors of heart failure and cardiovascular diseases. This suggests that serum H-FABP levels may reflect latent myocardial damage.
Discussion
In the present study, we showed that gender, age, BP, BMI, renal function, and ECG abnormality were important determinants of serum H-FABP levels in a general Japanese population.
Effect of Gender and Age on H-FABP Levels
Although men had higher serum H-FABP levels than women, the physiologic basis for these gender-related differences is unclear. The fact that men have a relatively larger muscle mass than women might influence these results. Accordingly, we may need to evaluate the diagnostic usefulness of H-FABP separately in men and in women. The gender-related difference in H-FABP levels has important implications for the use of this test in clinical practice and future research.
We observed a striking increase in lower and upper percentile values for H-FABP with aging. Why does aging enhance H-FABP values? The increase in H-FABP levels with aging may reflect a higher prevalence of subclinical cardiac diseases such as heart failure and renal dysfunction in older subjects. This may be supported by the observation that older subjects had higher ECG abnormality score and lower CCr.
In addition, it has been reported that the aged myocardium might be exposed to local ischemia. 14 Aging has also been shown to produce a diffuse loss of ventricular myocytes, and then to burden the remaining myocytes with stress and hypertrophy causing ECG abnormality. Thus, serum H-FABP levels may increase with age due to mechanical overload on cardiac myocytes. In order to clarify this point, echocardiography and cardiac event follow-up are necessary in a future study.
Influence of Biological Variations on Serum H-FABP Levels
The positive association of serum H-FABP levels with systolic and diastolic BP may suggest that BP affects serum H-FABP levels. BP was positively associated with serum H-FABP levels in both the univariate and multivariate analyses, although the association was weak. Previous studies reported a positive relationship between heart failure and hypertension. 15, 16 Collectively, these data may suggest that hypertension is one of the causes of sustained ongoing myocardial damage.
We observed a positive relationship between ECG abnormality scores and serum H-FABP levels by both the multiple regression analysis and multiple logistic regression models. This may indicate that elevated serum H-FABP represents latent cardiac injury. Although heart failure is usually progressive, it can remain asymptomatic for many years. Thus, it would be of benefit to identify latent patients who have asymptomatic heart failure by measuring serum H-FABP levels. Since it is difficult and expensive to carry out Doppler echocardiography or exercise tolerance testing in the general large population, we believe that H-FABP is a useful tool for screening patients with latent CHF.
As reported in brain natriuretic peptide, 17 there was a correlation between serum H-FABP levels and renal function in the present study. Since renal function is an important determinant of future cardiac events in patients with heart failure, 18 these data may also support the cardio-renal association in cardiac diseases.
Study Limitations
First, we did not examine echocardiography, because an ECG is a more convenient and inexpensive method than an echocardiography, and people aged 40 years or greater in Japan are able to have an annual ECG recording under the Health and Medical Service Law for the Aged or the Industrial Safety and Health Law. Second, cardiothoracic ratio data from chest X-rays were not available in this study population. Third, our study used a cross-sectional design, which does not prove causal relations between serum H-FABP levels and the above-mentioned risk factors.
Conclusions
In conclusion, this study shows for the first time that H-FABP levels are affected by age, gender, and ECG abnormality in a large group of volunteers. These results should be taken into account in determining appropriate reference values for H-FABP. It will aid in the precise identification of elevated serum H-FABP levels in clinical practice. Since elevated serum H-FABP levels are associated with aging, hypertension, renal function, and ECG abnormality, serum H-FABP may have important clinical implications to detect latent cardiac injury.
